JP2015518006A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518006A5
JP2015518006A5 JP2015514242A JP2015514242A JP2015518006A5 JP 2015518006 A5 JP2015518006 A5 JP 2015518006A5 JP 2015514242 A JP2015514242 A JP 2015514242A JP 2015514242 A JP2015514242 A JP 2015514242A JP 2015518006 A5 JP2015518006 A5 JP 2015518006A5
Authority
JP
Japan
Prior art keywords
human
allergic condition
composition
hydrochloride
performed via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015514242A
Other languages
English (en)
Other versions
JP2015518006A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/042925 external-priority patent/WO2013177594A2/en
Publication of JP2015518006A publication Critical patent/JP2015518006A/ja
Publication of JP2015518006A5 publication Critical patent/JP2015518006A5/ja
Pending legal-status Critical Current

Links

Claims (9)

  1. ヒトにおけるアレルギー状態を治療する方法であって、以下の工程、
    アレルギー状態を有するヒトを同定する工程、及び
    アレルギー状態を有する前記ヒトに、クロモグリク酸ナトリウム、塩酸フェニレフリン、塩酸オキシメタゾリン、塩酸アゼラスチン及びフロ酸モメタゾンの少なくとも1つの治療に有効な量から本質的になる組成物を投与して、アレルギー状態を有する前記ヒトの該アレルギー状態を治療する工程であって、前記組成物が、該アレルギー状態を治療するためのクロモグリク酸ナトリウム、塩酸フェニレフリン、塩酸オキシメタゾリン、塩酸アゼラスチン及びフロ酸モメタゾンの前記少なくとも1つによって生じる鼻乾燥を低下するための、キシリトール、エリスリトール、マンニトール、マルチトール、ティビトール、アラビトール、リボース及びキシロースの少なくとも1つの治療に有効な量から更に本質的になる工程、
    から本質的になることを特徴とする方法。
  2. 前記組成物が、水溶液である請求項1に記載の方法。
  3. アレルギー状態を有する前記ヒトへの投与工程が、前記組成物を、該ヒトの鼻、目、口、及び喉のうちの少なくとも1つに送達することを介して行われる請求項1に記載の方法。
  4. 前記組成物が、経鼻溶液である請求項1に記載の方法。
  5. アレルギー状態を有する前記ヒトへの投与工程が、前記ヒトの鼻に前記経鼻溶液を送達することを介して行われる、請求項4に記載の方法。
  6. 前記組成物が、ゲルである、請求項4に記載の方法。
  7. アレルギー状態を有する前記ヒトへの投与工程が、ゲルを接着送達方法で送達することを介して行われる、請求項6に記載の方法。
  8. アレルギー状態を有する前記ヒトへの投与工程が、鼻噴霧瓶、ドロッパ、ミスター、アトマイザー、ブラッシ及びスワブの少なくとも1つを介して行われる請求項1に記載の方法。
  9. 前記組成物が、自由に流れる低粘度の水溶液である請求項8に記載の方法。
JP2015514242A 2012-05-25 2013-05-28 キシリトール系の抗粘膜組成物及び関連する方法並びに組成物 Pending JP2015518006A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651741P 2012-05-25 2012-05-25
US61/651,741 2012-05-25
PCT/US2013/042925 WO2013177594A2 (en) 2012-05-25 2013-05-28 Xylitol-based anti-mucosal compositions and related methods and compositions

Publications (2)

Publication Number Publication Date
JP2015518006A JP2015518006A (ja) 2015-06-25
JP2015518006A5 true JP2015518006A5 (ja) 2017-03-23

Family

ID=49621806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514242A Pending JP2015518006A (ja) 2012-05-25 2013-05-28 キシリトール系の抗粘膜組成物及び関連する方法並びに組成物

Country Status (13)

Country Link
US (3) US8709508B2 (ja)
EP (1) EP2854781A4 (ja)
JP (1) JP2015518006A (ja)
KR (1) KR20150011807A (ja)
CN (1) CN104334164A (ja)
AU (1) AU2013266067B2 (ja)
BR (1) BR112014029442A2 (ja)
CA (1) CA2870158C (ja)
IL (1) IL235875A (ja)
MX (1) MX2014013998A (ja)
RU (1) RU2607892C2 (ja)
WO (1) WO2013177594A2 (ja)
ZA (1) ZA201408594B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
CA2870158C (en) 2012-05-25 2017-10-24 Xlear, Inc. Xylitol-based anti-mucosal compositions and related methods and compositions
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
WO2014066318A1 (en) 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
JP6545148B2 (ja) 2013-03-13 2019-07-17 フラットリー ディスカバリー ラブ,エルエルシー ピリダジノン化合物及び嚢胞性線維症の治療のための方法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3725311A1 (en) 2014-02-10 2020-10-21 Respivant Sciences GmbH Methods for the treatment of lung diseases with mast cell stabilizers
US20150224077A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, including Mast Cell Related Disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2018009889A1 (en) * 2016-07-07 2018-01-11 Xlear, Inc Antibacterial nasal compositions and related methods
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
CA3070386A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
US10799481B1 (en) 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
US11602541B2 (en) 2020-04-24 2023-03-14 Joseph Scivoletto Nasal spray composition
WO2022140795A2 (en) * 2020-12-23 2022-06-30 Spotlight Therapeutics Nucleic acid binding protein formulations and uses thereof
CN116211884B (zh) * 2023-02-16 2024-05-17 海孵(海南自贸区)医疗科技有限责任公司 一种鼻腔喷雾剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01172324A (ja) * 1987-12-15 1989-07-07 Armour Internatl Co コレスチラミン組成物及びその製造法
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下1▼―ブロッカー点眼剤
IL131492A0 (en) * 1997-04-30 2001-01-28 Warner Lambert Co Topical nasal antiinflammatory compositions
US6054143A (en) * 1998-03-24 2000-04-25 Jones; Alonzo H. Xylitol delivery
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
MXPA06001776A (es) * 2003-08-15 2007-09-07 Qlt Usa Inc Sistema de suministro de farmaco transmucosal biocorrosivo, adhesivo.
US20060034947A1 (en) 2004-06-02 2006-02-16 Burr James B Erythritol compositions for nasopharynx cleansing
DK2486942T3 (en) * 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
US20070286813A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US20100099650A1 (en) * 2006-10-10 2010-04-22 Knauer Kent A Nasal spray composition and method for treating rhinitis, sinusitis or both
DE202010012255U1 (de) * 2010-09-07 2010-11-18 Krewel Meuselbach Gmbh Nasenspray
CA2870158C (en) 2012-05-25 2017-10-24 Xlear, Inc. Xylitol-based anti-mucosal compositions and related methods and compositions

Similar Documents

Publication Publication Date Title
JP2015518006A5 (ja)
US8709508B2 (en) Xylitol-based anti-mucosal compositions and related methods and compositions
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
EA201491844A1 (ru) Распыляющие спрей эжекторные механизмы и устройства, выполненные с изоляцией и возможностью управляемого создания заряда на каплях, и нанесение малообъемных доз офтальмологических средств
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
HRP20171739T1 (hr) Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
ME02495B (me) Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
MX2015015589A (es) Composiciones y metodos para el suministro de agentes activos hidrófobos.
JP2015534562A5 (ja)
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
HRP20192010T1 (hr) Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja
JP2016525548A5 (ja)
WO2010024956A3 (en) Antihistamine and antihistamine-like nasal application, products, and method
CL2012001402A1 (es) Composicion farmaceutica en suspension oftalmica acuosa de administracion topica que comprende polimero de carboxivinilo, galactomanana, borato, compuesto en nanoparticulas escasamente soluble, agentes para ajustar ph y tonicidad, conservante y quelante; metodo para tratar trastornos oftalmicos, metodo para mantener viscosidad.
BR112015007360A2 (pt) composição farmacêutica, e, método para a preparação de uma droga de combinação
CO6400184A2 (es) Formulaciones galénicas de compuestos orgánicos
BR112014005538A2 (pt) composições aquosas compreendendo arbecacina
BR112013019876A2 (pt) formulação farmacêutica, uso da formulação farmacêutica, frasco e kit
JP2016502991A5 (ja)
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
BR112015030341A2 (pt) formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície
JP2014530847A5 (ja)